Actor-filmmaker Ramesh Aravind, who is directing the Kannada version of the film, will also direct the Tamil version. 
Entertainment News

It will be Queen, but not Queen: Ramesh Aravind

Director is done with most of shoot for Kannada version of Butterfly;He is heading to Madurai soon to work with Kajal Aggarwal

From our online archive

Director Ramesh Aravind has been busy directing Queen remakes in Kannada and Tamil and has successfully completed most of the films’ shoot.The Kannada version with Parul Yadav titled Butterfly was partly shot in Gokarna, and the remaining that was set in Europe was shot simultaneously for Tamil and Kannada versions. “I have one song left to shoot in Paris, for which I will go back in March. After that, I will have a bit of patch work to complete,” says the director.

Ramesh Arvind, Kajal Aggarwal

The filmmakers have shared Parul’s look during her portions in Gokrana. Clad in langa-blouse, Parul looks every bit a Kannada girl. Ramesh Aravind says that the movie “will be Queen, but not Queen”.

The director is glad to have music director Amit Trivedi on board, who is debuting in Sandalwood through this film. “Though he has done the original tunes for the Bollywood film  Queen, he has given all new and spectacular tunes for the remakes.

Lyrics written by Jayanth Kaikini adds value to the songs,” he says.Meanwhile, for the Tamil remake titled Paris Paris, Ramesh has completed shoot with Kajal Aggarwal in Paris. “The scenes I shot in Gokarna with Parul will be shot again with Kajal in Virudunagar, Madurai,” he says.The film in Kannada and Tamil also features Elli AvrRam, Varun Shashi in the cast and has Sathya Hegde handling the camerawork.

Why the additional declaration linked to Form 6 is facing a legal challenge

Four CISF personnel killed in firing by colleague after argument in J&K's Kathua

INDIA bloc meeting on SIR: Joint agitation, Gyanesh Kumar removal notice on agenda

India in talks with China for alternative route amid Pakistan airspace closure

SC slams medicine pricing, calls cancer drug’s 10-fold MRP markup ‘carnage’